AIM Stock Price, AIM ImmunoTech Inc Quote, Chart

Market Summary

USD0.39-0.02

Market Closed

-4.88%

AIM Stock Price

View Fullscreen

AIM RSI Chart

AIM Valuation

Market Cap

19.5M

Price/Earnings (Trailing)

-0.67

Price/Sales (Trailing)

96.34

Price/Free Cashflow

-0.92

AIM Price/Sales (Trailing)

AIM Profitability

Operating Margin

-672.28%

Return on Equity

-283%

Return on Assets

-149.44%

Free Cashflow Yield

-109.28%

AIM Fundamentals

AIM Revenue

Revenue (TTM)

202.0K

Rev. Growth (Yr)

15.04%

Rev. Growth (Qtr)

41.3%

AIM Earnings

Earnings (TTM)

-29.0M

Earnings Growth (Yr)

-186.53%

Earnings Growth (Qtr)

-60.9%

Breaking Down AIM Revenue

Last 7 days

-9.3%

Last 30 days

-20.4%

Last 90 days

-11.4%

Trailing 12 Months

-19.6%

How does AIM drawdown profile look like?

AIM Financial Health

Current Ratio

1.68

Debt/Equity

0.18

Debt/Cashflow

-11.71

AIM Investor Care

Shares Dilution (1Y)

3.09%

Diluted EPS (TTM)

-0.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	156.5K	168.5K	193.5K	202.0K
2022	167.0K	146.0K	134.0K	140.5K
2021	190.0K	201.0K	198.0K	206.0K
2020	950.0K	961.0K	936.0K	163.0K
2019	0	832.0K	860.0K	1.6M
2018	409.0K	229.0K	177.0K	859.0K
2017	178.3K	264.5K	350.8K	437.0K
2016	122.8K	112.5K	102.3K	92.0K
2015	558.6K	345.8K	239.4K	133.0K
2014	765.8K	715.4K	690.2K	665.0K
2013	1.1M	0	970.0K	791.0K
2012	1.3M	0	0	1.3M
2011	669.3K	1.2M	1.7M	2.3M
2010	0	0	0	135.0K
2009	0	0	0	111.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of AIM ImmunoTech Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 21, 2024	bryan nancy	bought	15,000	0.39	38,462	-
Mar 15, 2024	appelrouth stewart	bought	30,000	0.33	90,910	-
Mar 15, 2024	rodino peter w iii	bought	12,500	0.33	37,879	coo, secretary, gen. counsel
Mar 15, 2024	equels thomas k	bought	25,000	0.33	75,758	ceo & president
Nov 27, 2023	equels thomas k	bought	15,000	0.443	33,861	ceo & president
Sep 29, 2023	equels thomas k	bought	10,000	0.441	22,676	ceo & president
Aug 25, 2023	equels thomas k	bought	5,500	0.669	8,222	ceo & president
Aug 24, 2023	equels thomas k	bought	10,000	0.667	14,993	ceo & president
Jul 17, 2023	equels thomas k	bought	10,000	0.59	16,950	ceo & president
Mar 10, 2023	appelrouth stewart	sold	-83,895	1.23	-68,208	-

Which funds bought or sold AIM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-11,116	-	-%
Apr 24, 2024	SNS Financial Group, LLC	sold off	-100	-4,399	-	-%
Apr 23, 2024	ForthRight Wealth Management, LLC	unchanged	-	622	9,420	-%
Apr 18, 2024	SeaCrest Wealth Management, LLC	reduced	-5.4	207	16,515	-%
Apr 17, 2024	D.B. Root & Company, LLC	unchanged	-	375	5,676	-%
Apr 12, 2024	Traynor Capital Management, Inc.	unchanged	-	366	5,547	-%
Apr 12, 2024	AdvisorNet Financial, Inc	unchanged	-	16.00	236	-%
Apr 05, 2024	CWM, LLC	unchanged	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-30,030	874,831	-%
Feb 26, 2024	Virtu Financial LLC	reduced	-46.43	-6,000	7,000	-%

Are Funds Buying or Selling AIM?

Are funds buying AIM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AIM

No. of Funds

Unveiling AIM ImmunoTech Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 03, 2024	deutsch todd	3.5%	1,716,100	SC 13D/A
Aug 28, 2023	deutsch todd	3.5%	1,716,100	SC 13D/A
Aug 07, 2023	deutsch todd	3.5%	1,716,100	SC 13D/A
Jul 27, 2023	deutsch todd	3.5%	1,716,100	SC 13D
Feb 08, 2021	hudson bay capital management lp	0.02%	7,747	SC 13G/A
Feb 14, 2020	anson funds management lp	4.9%	434,030	SC 13G/A
Jan 31, 2020	hudson bay capital management lp	9.99%	917,198	SC 13G
Sep 30, 2019	anson funds management lp	9.9%	1,277,222	SC 13G

Recent SEC filings of AIM ImmunoTech Inc

View All Filings

Date Filed	Form Type	Document
May 01, 2024	424B5	Prospectus Filed
Apr 19, 2024	S-1	Initial Public Offering
Apr 01, 2024	10-K	Annual Report
Mar 27, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Feb 21, 2024	D/A	D/A

Peers (Alternatives to AIM ImmunoTech Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	5.56%	-15.17%	-9.03	6.22	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.9B	1.8B	-2.25%	-24.69%	-42.88	10.32	76.23%	61.08%
BMRN	15.8B	2.5B	-4.35%	-11.20%	76.99	6.4	13.74%	186.89%
INCY	11.9B	3.8B	-6.50%	-24.30%	15.95	3.16	8.58%	129.81%
MID-CAP
APLS	5.6B	396.6M	-22.91%	-44.64%	-10.5	14	425.83%	18.94%
BBIO	4.8B	-	-9.87%	93.55%	-7.28	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-2.73%	5.06%	-14.83	13.11	440.80%	-27.84%
ARWR	2.9B	240.7M	-18.02%	-34.57%	-9.67	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.68%	-20.30%	-45.84	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.49%	-8.60%	25.07	4.5	85.90%	-14.05%
NVAX	652.2M	983.7M	0.22%	-33.81%	-1.2	0.66	-50.36%	17.16%
CRBP	390.9M	881.7K	-1.95%	364.46%	-8.76	466.16	-77.61%	-5.33%
INO	270.2M	4.9M	-11.89%	28.44%	-2	55.51	-54.97%	51.71%
IBIO	6.4M	2.1M	-44.78%	68.18%	-0.24	2.14	-13.45%	66.37%

AIM ImmunoTech Inc News

Latest updates

AIM ImmunoTech Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4	2018Q3
Revenue	41.3%	65.00	46.00	42.00	49.00	57.00	21.00	30.00	33.00	50.00	33.00	51.00	72.00	42.00	36.00	40.00	45.00	815	61.00	29.00	732	38.00
Costs and Expenses	71.5%	14,069	8,203	5,503	4,344	5,612	6,542	4,725	3,185	7,496	3,962	3,741	3,773	5,183	3,391	3,380	3,370	3,138	3,266	3,253	2,901	3,076
S&GA Expenses	99.6%	10,857	5,439	2,550	2,292	3,578	5,170	2,181	2,072	2,617	1,799	2,145	2,112	2,584	2,085	1,717	2,268	1,484	1,846	1,942	1,632	1,273
R&D Expenses	17.0%	3,200	2,734	2,953	2,052	-4,605	1,372	2,475	1,036	-	2,006	1,317	1,424	2,275	1,102	1,463	898	1,437	1,190	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-1.00	19.00	50.00	53.00	51.00	249	322	-	-	-	-	-
Net Income	-60.9%	-12,576	-7,816	-4,909	-3,661	-4,389	-6,385	-4,851	-3,820	-5,746	-3,826	-5,913	-3,742	-3,965	-3,306	-3,303	-3,794	-527	-2,948	-2,036	-1,621	-3,078
Net Income Margin	-33.5%	-143.38*	-107.36*	-114.80*	-123.23*	-138.40*	-155.24*	-124.95*	-115.60*	-93.33*	-98.85*	-79.65*	-71.05*	-82.34*	-11.28*	-	-	-	-	-	-	-
Free Cashflow	-72.1%	-9,758	-5,671	-2,165	-3,687	-6,076	-4,975	-2,320	-2,765	-5,752	-3,465	-1,727	-3,054	-2,863	-2,993	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-30.4%	19.00	28.00	34.00	37.00	40.00	46.00	51.00	54.00	58.00	63.00	67.00	74.00	65.00	64.00	50.00	42.00	21.00	22.00	14.00	16.00	14.00
Current Assets	-36.0%	15.00	23.00	29.00	33.00	36.00	41.00	46.00	50.00	50.00	38.00	41.00	51.00	40.00	40.00	35.00	30.00	10.00	13.00	4.00	6.00	4.00
Cash Equivalents	-64.4%	5.00	15.00	21.00	23.00	27.00	30.00	34.00	29.00	32.00	37.00	41.00	49.00	39.00	38.00	34.00	28.00	1.00	10.00	1.00	2.00	0.00
Net PPE	-6.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.00	6.00	6.00	6.00	6.00	7.00	7.00	7.00	7.00	7.00	7.00	8.00	8.00
Current Liabilities	83.5%	9.00	5.00	3.00	2.00	1.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	4.00	2.00	2.00	5.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Shareholder's Equity	-54.7%	10.00	23.00	30.00	35.00	38.00	43.00	49.00	53.00	57.00	62.00	66.00	71.00	61.00	61.00	47.00	35.00	13.00	13.00	7.00	4.00	6.00
Retained Earnings	-3.2%	-409	-396	-389	-384	-380	-376	-369	-364	-361	-355	-351	-345	-341	-338	-335	-331	-327	-326	-323	-321	-318
Additional Paid-In Capital	0.0%	419	419	419	418	418	418	418	417	417	417	416	416	403	399	381	366	340	340	329	323	324
Shares Outstanding	0.6%	49.00	49.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	42.00	41.00	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	36.00	-	-	-	101	-	-	-	84.00	-	-	-	10.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-72.1%	-9,758	-5,671	-2,158	-3,680	-6,069	-4,968	-2,313	-2,758	-5,745	-3,457	-1,718	-3,045	-2,854	-2,989	-1,275	-3,250	-2,289	-2,544	-2,777	-1,457	-2,419
Share Based Compensation	22.0%	61.00	50.00	50.00	82.00	162	275	275	242	248	314	480	526	440	250	150	196	204	223	251	175	178
Cashflow From Investing	36.3%	-214	-336	-204	-78.00	3,363	250	7,721	-346	364	-366	-1,152	523	-182	-9,583	-3,082	3,683	-5,289	-232	472	-1,098	-1,518
Cashflow From Financing	-36.9%	147	233	5.00	100	-	25.00	-	-	125	30.00	-4,761	12,794	3,041	17,160	10,675	25,687	-568	11,433	870	4,650	181

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AIM Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Clinical treatment programs – US	$ 202	$ 141
Total Revenues	202	141
Costs and Expenses:
Production costs	42
Research and development	10,939	6,990
General and administrative	21,137	13,074
Total Costs and Expenses	32,118	20,064
Operating loss	(31,916)	(19,923)
Gain (loss) on investments	200	(1,679)
Interest and other income	1,069	629
Gain on sale of fixed assets	18	3
Redeemable warrants valuation adjustment		35
Gain from sale of income tax operating losses	1,667	1,490
Net Loss	$ (28,962)	$ (19,445)
Basic loss per share	$ (0.60)	$ (0.40)
Diluted loss per share	$ (0.60)	$ (0.40)
Weighted average shares outstanding basic	48,585,404	48,047,288
Weighted average shares outstanding diluted	48,585,404	48,047,288

AIM Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 5,439,000	$ 27,053,000
Marketable investments	7,631,000	7,137,000
Funds receivable from New Jersey net operating loss	1,184,000	1,676,000
Prepaid expenses and other current assets	302,000	455,000
Total current assets	14,556,000	36,321,000
Property and equipment, net	127,000	195,000
Right of use asset, net	697,000	829,000
Patent and trademark rights, net	2,313,000	1,941,000
Other assets	1,688,000	1,202,000
Total assets	19,381,000	40,488,000
Current liabilities:
Accounts payable	6,443,000	377,000
Accrued expenses	1,986,000	806,000
Current portion of operating lease liability	223,000	178,000
Total current liabilities	8,652,000	1,361,000
Long-term liability:
Operating lease liability	495,000	659,000
Total liabilities	9,147,000	2,020,000
Commitments and contingencies (Notes 8, 10, 11, 16)
Stockholders’ equity:
Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 49,102,484 and 48,084,287 (including 701,667 and 694,324 of unvested stock awards) as of December 31, 2023 and 2022, respectively	49,000	48,000
Additional paid-in capital	419,004,000	418,270,000
Accumulated deficit	(409,508,000)	(380,546,000)
Total stockholders’ equity	10,234,000	38,468,000
Total liabilities and stockholders’ equity	19,381,000	40,488,000
Series A Junior Participating Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock, Value
Series B Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock, Value	$ 689,000	$ 696,000

About AIM ImmunoTech Inc

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

CEO	Mr. Thomas K. Equels Esq., J.D., M.S.
WEBSITE	https://aimimmuno.com
INDUSTRY	Biotechnology
EMPLOYEES	22

AIM ImmunoTech Inc Frequently Asked Questions

What is the ticker symbol for AIM ImmunoTech Inc? What does AIM stand for in stocks?

AIM is the stock ticker symbol of AIM ImmunoTech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AIM ImmunoTech Inc (AIM)?

As of Wed May 01 2024, market cap of AIM ImmunoTech Inc is 19.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AIM stock?

You can check AIM's fair value in chart for subscribers.

What is the fair value of AIM stock?

You can check AIM's fair value in chart for subscribers. The fair value of AIM ImmunoTech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AIM ImmunoTech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AIM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AIM ImmunoTech Inc a good stock to buy?

The fair value guage provides a quick view whether AIM is over valued or under valued. Whether AIM ImmunoTech Inc is cheap or expensive depends on the assumptions which impact AIM ImmunoTech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AIM.

What is AIM ImmunoTech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 01 2024, AIM's PE ratio (Price to Earnings) is -0.67 and Price to Sales (PS) ratio is 96.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AIM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AIM ImmunoTech Inc's stock?

In the past 10 years, AIM ImmunoTech Inc has provided -0.459 (multiply by 100 for percentage) rate of return.